Sign Up! | Tags | Domains | Statistics | Options | Advanced Search
|
Sign Up! | Tags | Domains | Statistics | Options | Advanced Search |
xconomy.com » Xconomy Boston - Oct 23, 2008
Roundup, Life Sciences, VC Rebecca Zacks wrote: There was a lot of activity related to biotech-pharma partnerships this week. That, and the rest of the Boston-area life sciences news, below. —Lexington, MA-based …
Also tagged: drugs, people, roundup, vc, boston, deals, startups, fda, merck, new enterprise associates, mayo clinic, eli lilly, pharma, dyax, life sciences, genzyme, biogen idec, polaris venture partners, highland capital partners, in q tel, boston blog main, flagship ventures, national blog main, flybridge capital partners, vertex pharmaceuticals, archemix, infinity pharmaceuticals, predictive biosciences, ariad pharmaceuticals, henry blair, kaiser permanente ventures, t2 biosystems, gustav christensen, frederic chereau, pervasis therapeutics immunogen
xconomy.com » Xconomy Life Sciences Feed - Oct 22, 2008
Roundup, Life Sciences, VC Rebecca Zacks wrote: There was a lot of activity related to biotech-pharma partnerships this week. That, and the rest of the Boston-area life sciences news, below. —Lexington, MA-based …
Also tagged: drugs, people, roundup, vc, boston, deals, startups, fda, merck, new enterprise associates, mayo clinic, eli lilly, pharma, dyax, life sciences, genzyme, biogen idec, polaris venture partners, highland capital partners, in q tel, boston blog main, flagship ventures, national blog main, flybridge capital partners, vertex pharmaceuticals, archemix, infinity pharmaceuticals, predictive biosciences, ariad pharmaceuticals, henry blair, kaiser permanente ventures, t2 biosystems, gustav christensen, frederic chereau, pervasis therapeutics immunogen
xconomy.com » Xconomy Venture Capital Feed - Oct 21, 2008
Roundup, Life Sciences, VC Rebecca Zacks wrote: There was a lot of activity related to biotech-pharma partnerships this week. That, and the rest of the Boston-area life sciences news, below. —Lexington, MA-based …
Also tagged: drugs, people, roundup, vc, boston, deals, startups, fda, merck, new enterprise associates, mayo clinic, eli lilly, pharma, dyax, life sciences, genzyme, biogen idec, polaris venture partners, highland capital partners, in q tel, boston blog main, flagship ventures, national blog main, flybridge capital partners, vertex pharmaceuticals, archemix, infinity pharmaceuticals, predictive biosciences, ariad pharmaceuticals, henry blair, kaiser permanente ventures, t2 biosystems, gustav christensen, frederic chereau, pervasis therapeutics immunogen
xconomy.com » Xconomy Boston - Oct 20, 2008
Roundup, deals, VC Rebecca Zacks wrote: Last week had a little bit of everything for Boston-area deals watchers. —Lexington, MA-based cancer drug developer Synta Pharmaceuticals (NASDAQ: SNTA) got a $25 million …
Also tagged: energy, software, roundup, biotech, vc, boston, glaxosmithkline, mit, solar, deals, startups, new enterprise associates, gt solar, cleantech, charles river ventures, webaroo, polaris venture partners, highland capital partners, massachusetts general hospital, evergreen solar, synta pharmaceuticals, electro scientific industries, robert langer, in q tel, helion venture partners, managed objects, boston blog main, flagship ventures, national blog main, flybridge capital partners, predictive biosciences, core capital, kaiser permanente ventures, zygo, t2 biosystems, v i labs, ascent ventures, aee solar, top green energy technologies, mainstream energy corporation
xconomy.com » Xconomy Energy Feed - Oct 19, 2008
Roundup, deals, VC Rebecca Zacks wrote: Last week had a little bit of everything for Boston-area deals watchers. —Lexington, MA-based cancer drug developer Synta Pharmaceuticals (NASDAQ: SNTA) got a $25 million …
Also tagged: energy, software, roundup, biotech, vc, boston, glaxosmithkline, mit, solar, deals, startups, new enterprise associates, gt solar, cleantech, charles river ventures, webaroo, polaris venture partners, highland capital partners, massachusetts general hospital, evergreen solar, synta pharmaceuticals, electro scientific industries, robert langer, in q tel, helion venture partners, managed objects, boston blog main, flagship ventures, national blog main, flybridge capital partners, predictive biosciences, core capital, kaiser permanente ventures, zygo, t2 biosystems, v i labs, ascent ventures, aee solar, top green energy technologies, mainstream energy corporation
 |
Funding Round Two for T2 and Its Pint-Sized Diagnostic Devicesxconomy.com » Xconomy Boston - Oct 18, 2008 startups, VC, Diagnostics Rebecca Zacks wrote: T2 Biosystems, a Cambridge, MA-based startup founded by a cadre local life sciences legends, today announced it has closed a $10.8 million Series B financing round … Also tagged: diagnostics, biotech, vc, boston, startups, polaris venture partners, robert langer, in q tel, boston blog main, ralph weissleder, john mcdonough, tyler jacks, flagship ventures, national blog main, flybridge capital partners, stanley lapidus, t2 biosystems |
|
Funding Round Two for T2 and Its Pint-Sized Diagnostic Devicesxconomy.com » Xconomy Life Sciences Feed - Oct 17, 2008 startups, VC, Diagnostics Rebecca Zacks wrote: T2 Biosystems, a Cambridge, MA-based startup founded by a cadre local life sciences legends, today announced it has closed a $10.8 million Series B financing round … Also tagged: diagnostics, biotech, vc, boston, startups, polaris venture partners, robert langer, in q tel, boston blog main, ralph weissleder, john mcdonough, tyler jacks, flagship ventures, national blog main, flybridge capital partners, stanley lapidus, t2 biosystems |
 |
Provasculon, a Biogen-backed Startup, Testing Regenerative Medicine on Heartsxconomy.com » Xconomy Boston - Oct 10, 2008 Biotech, Heart Disease, Biogen Idec Luke Timmerman wrote: Provasculon is tackling one of the bigger ideas in regenerative medicine—how to stimulate growth of new blood vessels after they’ve been damaged by a heart … Also tagged: biotech, boston, heart disease, stem cells, life sciences, genzyme, biogen idec, massachusetts general hospital, richard lee, boston blog main, national blog main, naomi aoki, brigham and 38 women s hospital, bioheart, provasculon, vincent segers, sdf 1, anthony sandrasagra |
xconomy.com » Xconomy Life Sciences Feed - Oct 9, 2008
Biotech, Heart Disease, Biogen Idec Luke Timmerman wrote: Provasculon is tackling one of the bigger ideas in regenerative medicine—how to stimulate growth of new blood vessels after they’ve been damaged by a heart …
Also tagged: biotech, boston, heart disease, stem cells, life sciences, genzyme, biogen idec, massachusetts general hospital, richard lee, boston blog main, national blog main, naomi aoki, brigham and 38 women s hospital, bioheart, provasculon, vincent segers, sdf 1, anthony sandrasagra
xconomy.com » Xconomy - Sep 7, 2008
VC, Life Sciences, Devices Ryan McBride wrote: Some of the most exclusive clubs in the Boston area aren’t actually clubs at all, they are venture capital firms, where partners hold the power to turn ideas into …
Also tagged: people, devices, vc, boston, glaxosmithkline, novartis, amgen, siemens, life sciences, genzyme, biogen idec, covidien, boston blog main, national blog main, proteostasis